Medpace (MEDP) -15.9% to $446 | RSI 9.6 | Market Cap $12.6B

Quality CRO compounder capitulated today on book-to-bill deterioration and growth guide-down. But the headline numbers hide a >$3B pre-backlog pipeline (larger than reported backlog, up 30% YoY) that management disclosed on Q3 call but isn't showing up in the stock reaction.

What Happened

Q4 2025 results (8-K filed Feb 9, 10-K filed Feb 10):

  • Revenue $708.5M (+32% YoY) - accelerating growth, beat by 10.5%
  • EPS $4.67 vs $4.23 est - solid beat
  • Book-to-bill 1.04x (down sharply from Q3 record 1.20x)
  • Backlog $3.03B (+4.3% YoY) - barely growing despite 20% revenue growth
  • No share repurchases in Q4 (despite $821.7M authorization remaining)

2026 guidance disappoints:

  • Revenue $2.755-2.855B (midpoint +10.8%)
  • Deceleration from 20% growth in 2025 to ≈11% in 2026
  • EPS $16.68-17.50 (excludes any buyback impact - with $821.7M authorization, actual likely higher)
  • EBITDA margin ≈22% (flat with 2025)

CEO Troendle sold >$77M Nov-Dec 2025 across multiple transactions. Buyback pause in Q4.

Stock reaction: -15.9% on 4x volume to RSI 9.6. Analyst consensus: 8 hold, 4 sell, only 1 buy.

The Hidden Data Point

From Q3 2025 call (Oct 23):

"The overall pipeline of awarded studies... we've negotiated the price on it. They've given us written award of that. And it just hasn't gotten to first patient in yet... And that is up 30%. And this pre-backlog bucket of awarded work is larger than our backlog itself and is up 30% over the year."

Translation: >$3B of contracted work (fixed scope, negotiated price, firm written award) sits outside reported backlog. When studies start enrolling patients, this flows into backlog and then revenue.

The bull case: Book-to-bill dip is temporary - studies awarded but starting slower. Pre-backlog converts in 2026 → backlog refills → growth re-accelerates.

The bear case: Biotech funding crunch means small pharma clients can't fund trials. Pre-backlog cancels before converting (like H1 2025 pattern). Growth deceleration is structural.

The Concentration Risk

From 10-K: 82% of revenue from small biopharma, 13% from mid-sized - total 95% from non-large pharma.

Filing explicitly flags: "Small biopharmaceutical companies... may have limited access to capital."

In a biotech funding downturn, this is the vulnerability. Troendle on Q3 call: "This has been driven by cancellations, not weak business... despite all these huge cancellations... we still grew that bucket by 30%."

Q4 cancellations were "the highest in more than a year" per management.

Margin Compression Is Real

  • Q4 EBITDA margin 22.6% vs 24.9% prior year (-230bps)
  • Pass-through costs (reimbursed investigator expenses) surged 34.6% vs revenue growth of 20%
  • Driven by late-stage metabolic studies with higher site costs

Troendle Q3 call: "Pass-throughs to maybe peak in Q4 or so and come down over '26."

If metabolic mix persists, margins stay compressed. If mix normalizes, margins recover.

Sector Context

Entire CRO space oversold:

  • IQV (IQVIA) RSI 19.3, -24.3% 1M
  • ICLR (ICON) RSI 19.0, -19.8% 1M
  • CRL (Charles River) RSI 16.5, -17.2% 1M

This isn't MEDP-specific. Market is repricing CRO growth expectations across the board.

The Doorway State

Two patterns fit the evidence:

Pattern A - Temporary deceleration (bullish):

  • $3B pre-backlog converts in 2026

  • Pass-throughs normalize (Troendle guided to this)
  • Buybacks resume ($821.7M authorization = ≈7% of market cap)
  • Growth re-accelerates to mid-teens
  • At 24x forward P/E (ex-buyback), stock undervalued

Pattern B - Structural slowdown (bearish):

  • Biotech funding stays tight, small pharma can't fund trials
  • Pre-backlog cancels before converting (like 2024-2025)
  • Margin compression permanent (metabolic mix persists)
  • CEO selling >$77M is informed
  • At 24x for 11% growth with margin pressure, fairly valued

Catalyst timeline: Q1 2026 earnings (late April) reveals whether book-to-bill stabilizes and pass-throughs normalize. That's when the pattern collapses.

Valuation

At $446:

  • 24x forward P/E (guidance midpoint $17.09, likely higher with buybacks)
  • 29x trailing P/E
  • Premium to peers (IQV 23x, ICLR 19.5x)
  • Max pain $550 (+23% from current)

Quality metrics still strong:

  • Operating cash flow $713M (1.58x net income)
  • $497M cash, no debt
  • 20% revenue growth in 2025 (despite cancellations)
  • 4 consecutive quarters of EPS beats

The Question

Is the market correctly repricing from growth to value, or is it overreacting to a temporary deceleration while the >$3B pre-backlog pipeline (up 30% YoY, not in headline numbers) waits to convert?

Technical extreme (RSI 9.6, 4x volume) suggests capitulation. CEO selling >$77M ahead of deceleration is the red flag.

Earnings call today (Feb 10, 9am ET) will reveal management's tone on:

  1. Pre-backlog conversion timeline
  2. Pass-through normalization trajectory
  3. Buyback plans for 2026
  4. Biotech funding environment for small pharma clients

Risk/reward skews favorable if deceleration is temporary. Size for surviving the bear case.

Sources: